Binding and functional properties of the novel somatostatin analogue KE 108 at native mouse somatostatin receptors.
Clinically used somatostatin (SRIF) analogs, octreotide and lanreotide, act primarily by binding to SRIF receptor subtype 2 (sst2). In contrast, the recently described multiligand SOM230 binds with high affinity to sst(1-3) and sst5 and KE 108 is characterised as a high affinity ligand for all five SRIF receptors. In tumoural mouse corticotrophs (AtT-20 cells) and in mouse hippocampus, binding and functional features of KE 108 were examined and compared to SRIF-14, octreotide and SOM230. In AtT-20 cells, KE 108 bound with high affinity at [125I]LTT-SRIF-28-labelled sites similarly to SRIF-14, octreotide and SOM230. At the functional level, all four ligands increased guanosine-5'-O-(3-[35S]thio)-triphosphate binding and decreased cAMP accumulation or intracellular Ca2+ concentration through G(i/o) proteins. In hippocampal slices, KE 108, octreotide and SOM230 also bound with high affinity at [125I]LTT-SRIF-28-labelled sites similarly to SRIF-14, but KE 108, octreotide or SOM230 did not influence spontaneous epileptiform activity which was, in contrast, inhibited by SRIF-14. In conclusion, this study demonstrates that KE 108 has high affinity for native mouse SRIF receptors. Functionally, KE 108 mediates SRIF action at sst(2/5) in corticotrophs whereas it does not mimic the SRIF-induced inhibition of hippocampal excitation suggesting that the high potency and efficacy of a synthetic ligand to all known SRIF receptors may not reproduce entirely the effects of the natural SRIF.
Cervia
Davide
D
Dipartimento di Fisiologia e Biochimica G. Moruzzi, Università di Pisa, 56127 Pisa, Italy. d.cervia@dfb.unipi.it
Langenegger
Daniel
D
Schuepbach
Edi
E
Cammalleri
Maurizio
M
Schoeffter
Philippe
P
Schmid
Herbert A
HA
Bagnoli
Paola
P
Hoyer
Daniel
D
D000818:Animals; D002118:Calcium / Q000378:metabolism; D045744:Cell Line, Tumor; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D016257:Fura-2 / Q000031:analogs & derivatives* / Q000378:metabolism; D016244:Guanosine 5'-O-(3-Thiotriphosphate) / Q000494:pharmacology; D006624:Hippocampus / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D010456:Peptides, Cyclic / Q000737:chemistry / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D011869:Radioligand Assay / Q000379:methods; D017481:Receptors, Somatostatin / Q000187:drug effects*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors*; D013460:Sulfur Isotopes / Q000494:pharmacology; D013997:Time Factors
D010456:Peptides, Cyclic; D017481:Receptors, Somatostatin; D013460:Sulfur Isotopes; C473958:Tyr(0)-(cyclo-D-Dab-Arg-Phe-Phe-D-Trp-Lys-Thr-Phe); C049925:fura-2-am; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D013004:Somatostatin; D000242:Cyclic AMP; D002118:Calcium; D016257:Fura-2